Summit Creek Advisors LLC Has $16.20 Million Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Summit Creek Advisors LLC trimmed its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 13.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 175,859 shares of the medical instruments supplier's stock after selling 26,907 shares during the period. LeMaitre Vascular accounts for about 2.1% of Summit Creek Advisors LLC's investment portfolio, making the stock its 21st largest position. Summit Creek Advisors LLC owned approximately 0.78% of LeMaitre Vascular worth $16,204,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new position in shares of LeMaitre Vascular in the third quarter valued at approximately $265,000. Advisors Asset Management Inc. lifted its position in LeMaitre Vascular by 180.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier's stock worth $172,000 after acquiring an additional 1,191 shares during the last quarter. Intech Investment Management LLC bought a new stake in LeMaitre Vascular during the third quarter valued at about $377,000. Charles Schwab Investment Management Inc. boosted its holdings in LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock valued at $17,789,000 after acquiring an additional 11,395 shares during the period. Finally, Marco Investment Management LLC grew its position in shares of LeMaitre Vascular by 8.6% in the third quarter. Marco Investment Management LLC now owns 2,660 shares of the medical instruments supplier's stock valued at $247,000 after purchasing an additional 210 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. StockNews.com cut LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target on the stock. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $95.25.

Insider Buying and Selling at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $0.09 during midday trading on Thursday, reaching $84.43. 23,816 shares of the company's stock were exchanged, compared to its average volume of 147,927. The company's 50 day simple moving average is $93.67 and its two-hundred day simple moving average is $94.41. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58. The firm has a market capitalization of $1.90 billion, a PE ratio of 46.12, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be paid a dividend of $0.20 per share. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Thursday, March 13th. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.